<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Pediatric Ophthalmology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Pediatric Ophthalmology</journal-title><trans-title-group xml:lang="ru"><trans-title>Российская педиатрическая офтальмология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1993-1859</issn><issn publication-format="electronic">2412-432X</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">39591</article-id><article-id pub-id-type="doi">10.18821/1993-1859-2018-13-2-81-86</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">IMPORTANCE OF IMMUNOLOGICAL FACTORS IN THE DEVELOPMENT OF RETINOPATHY OF PREMATURITY</article-title><trans-title-group xml:lang="ru"><trans-title>ЗНАЧЕНИЕ ИММУНОЛОГИЧЕСКИХ ФАКТОРОВ В РАЗВИТИИ РЕТИНОПАТИИ НЕДОНОШЕННЫХ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kuznetsova</surname><given-names>Julia Dmytrievna</given-names></name><name xml:lang="ru"><surname>Кузнецова</surname><given-names>Юлия Дмитриевна</given-names></name></name-alternatives><bio xml:lang="en"><p>«Russian children’s Clinical Hospital Russian Ministry of Health, doctor of oftolmology department, The Highest category doctor, Moscow, 117997</p></bio><bio xml:lang="ru"><p>врач-офтальмолог отделения офтальмологии ФГБУ «РДКБ» Минздрава РФ. 117997, Москва</p></bio><email>kuznecovay@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Balashova</surname><given-names>L. M</given-names></name><name xml:lang="ru"><surname>Балашова</surname><given-names>Л. М</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bykovskaya</surname><given-names>S. N</given-names></name><name xml:lang="ru"><surname>Быковская</surname><given-names>С. Н</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian children’s Clinical Hospital Russian Ministry of Health</institution></aff><aff><institution xml:lang="ru">ФГБУ “Российская детская клиническая больница” Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">N.I. Pirogov Russian National Research Medical University Ministry of Health</institution></aff><aff><institution xml:lang="ru">ГБОУ ВПО «Российский национальный исследовательский медицинский Университет им. Н.И. Пирогова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-06-15" publication-format="electronic"><day>15</day><month>06</month><year>2018</year></pub-date><volume>13</volume><issue>2</issue><issue-title xml:lang="en">VOL 13, NO2 (2018)</issue-title><issue-title xml:lang="ru">ТОМ 13, №2 (2018)</issue-title><fpage>81</fpage><lpage>86</lpage><history><date date-type="received" iso-8601-date="2020-07-22"><day>22</day><month>07</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, ООО "Эко-Вектор"</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">ООО "Эко-Вектор"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://ruspoj.com/1993-1859/article/view/39591">https://ruspoj.com/1993-1859/article/view/39591</self-uri><abstract xml:lang="en"><p>Retinopathy of prematurity is one of the most severe multifactorial diseases eye deeply in preterm infants is associated with general and local morfofunkcional’noj immaturity and vazoproliferasion, often leading to blindness and low vision project and progressing during the entire life. Our review article focuses on the role of immunolological factors in the development of retinopathy of prematurity. The data obtained and further research to study the role of immunological parameters in the pathogenesis of retinopathy of prematurity and develop, on the basis of this, it caused by correction techniques to prevent the occurrence and progression of the disease remain a burning issue at present.</p></abstract><trans-abstract xml:lang="ru"><p>Ретинопатия недоношенных - одно из самых тяжелых многофакторных заболеваний глаз глубоко недоношенных детей, связанное с общей и локальной морфофункциональной незрелостью и вазопролиферацией, нередко приводящее к слепоте и слабовидению и прогрессирующее в течение всей жизни. Данная обзорная статья посвящена роли иммунолологических факторов в развитии ретинопатии недоношенных. Полученные разными авторами данные и дальнейшие исследования по изучению роли иммунологических показателей в патогенезе ретинопатии недоношенных и разработка, на основании этого, патогенетически обусловленных методик иммунокоррекции для профилактики возникновения и прогрессирования данного заболевания, остаются в настоящее время актуальной проблемой.</p></trans-abstract><kwd-group xml:lang="en"><kwd>retinopathy of prematurity</kwd><kwd>pathogenesis</kwd><kwd>immunological factors</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ретинопатия недоношеных</kwd><kwd>патогенез</kwd><kwd>иммунологические факторы</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Terry T.L. Fibroblastic overgrowth of persistent tunica vasculosa lentis in infants born prematurely stage 3. Studies in development and regression of hyaloids artery and tunica vasculosa lentis. Am. J. Ophthalmol. 1942; 25: 1409.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Дегтярева М.В., Дегтярев Д.Н., Володин Н.Н., Ковальчук Л.В. Роль интерлейкина-1 и фактора некроза опухолей новорожденных детей в норме и патологии. Педиатрия.1996; (1): 93-7.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Correa-Rocha R., Perez A., Lorente R., Ferrando-Martinez S., Leal M., et al. Preterm neonates show marked leukopenia and lymphopenia that are associated with increased regulatory T-cell values and diminished IL-7. Pediatr. Res. 2012; 71: 590-7</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Scheible K.M., Emo J., Yang H. et al. Developmentally determined reduction in CD31 during gestation is associated with CD8+ T cell effector differentiation in preterm infants. Clin. Immunol. 2015 Dec;161(2):65-74.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Siegrist C.A., Aspinall R. B-cell responses to vaccination at the extremes of age. Nat. Rev. Immunol.2009;9:185-94.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Катаргина Л.А. , Слепова О.С., Скрипец П.П. и др. Гуморальный иммунный ответ на S-антиген сетчатки и его роль в развитии и течении ретинопатии недоношенных. Вестн. офтальмол. 2003; ( 1): 20-2.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Hellstrom A., Smith L.E., Dammann O. “Retinopathy of prematurity”. Lancet. 2013 Oct 26;382(9902): 1445-57.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Sonmez K., Drenser K.A., Caoine A.Jr. , et al. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopayhy of prematurity. Ophthalmology. 2008; 115: 1065-70.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Langer H.F., Chung K.J., Orlova V.V. et al. Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood. 2010 Nov 25; 116 (22): 4395-403.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kurtul B.E., Kabatas E.U., Zenciroglu A., Ozer P.A., Ertugrul G.T., Beken S., Okumus N. Serum neutrophil-to-lymphocyte ratio in retinopathy of prematurity. J AAPOS. 2015 Aug; 19(4):327-31.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Слепова О.С., Катаргина Л.А., Гвоздюк Н.А., Белова М.В. Влияние системной продукции ростовых факторов (VEGF и fIGF-I ) на течение заболевания у детей с ретинопатией недношенных. Рос. офтальмол. журн. 2011; 4(4): 60-4.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Ferguson T.A., Apte R.S. Angiogenesis in eye disease: immunity gained or immunity lost? Semin Immunopathol. 2008; 30(2): 111-9.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Löfqvist C., Hansen-Pupp I., Andersson E., Holm K., Smith L.E., Ley D., Hellström A. Validation of a new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and insulinlike growth factor I. Arch Ophthalmol. 2009;127: 622-7.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Pérez-Muñuzuri A., Fernández-Lorenzo J.R., Couce-Pico M.L., Blanco-Teijeiro M.J., Fraga-Bermúdez J.M. Serum levels of IGF1 are a useful predictor of retinopathy of prematurity. Acta Paediatr. 2010; 99: 519-25.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Pieh C., Krüger M., Lagrèze W.A., Gimpel C., Buschbeck C., Zirrgiebel U., Agostini H.T. Plasma sE-selectin in premature infants: a possible surrogate marker of retinopathy of prematurity. Invest. Ophthalmol. Vis Sci. 2010; 51: 3709-13.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Bhola R., Purkiss T., Hunter S., Stewart D., Rychwalski P.J. Effect of granulocyte colony-stimulating factor on the incidence of threshold retinopathy of prematurity. J AAPOS. 2009; 13: 450-3.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Hellstrom A., Perruzzi C., Ju M. et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity. Proc. Natl Acad. Sci. USA. 2001; 98 (10): 5084-8.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Löfqvist C., Niklasson A., Engström E., Friberg L.E., Camacho-Hübner C., Ley D., Borg J., Smith L.E., Hellström A. A. Pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants. Pediatr Res. 2009;65: 574-9.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Mititelu M., Chaudhary K.M., Lieberman R.M. An evidence-based meta-analysis of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 1. Retinopathy of prematurity. J. Pediatr. Ophthalmol Strabismus. 2012; 49 :332-40.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Сидоренко Е.Е. Использование ингибиторов СЭФР при ретинопатии недоношенных / Иванова Н.М.,Шварова А.В.,Притыко А.Г. В кн.: Тезисы науч.-практ. конф. с междунар. участием «Ретинопатия недоношенных» 2016. Москва; 2016: 127-9.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Darlow B.A., Ells A., Gilbert G.C., Gole G., Quinn G. Are we there yet? Bevacizumab treatment for retinopathy of prematurity. Arch. Dis.Child.Fetal. Neonatal. Ed. Epub, 2011, December 30.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Isaac М., Tehrani N., Mireskandari K. Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up. Eye(Lond).2016Mar;30(3):333-41</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Mota A., Carneiro A., Breda J. et al. Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity. Case Rep. Ophthalmol. 2012; 3 ( 1): 136-41.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Hård A.L., Smith L.E., Hellström A. Nutrition, insulin-like growth factor-1 and retinopathy of prematurity. Semin Fetal. Neonatal. Med. 2013:Feb 18.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Ley D., Hansen-Pupp I., Niklasson A., Domellöf M., Friberg L.E., Borg J., Löfqvist C., Hellgren G., Smith L.E., Hård A.L., et al. Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: pharmacokinetics and short-term safety. Pediatr Res. 2013; 73: 68-74.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Sood B.G., Madan A., Saha S., Schendel D., Thorsen P., Skogstrand K., Hougaard D., Shankaran S., Carlo W. Perinatal systemic inflammatory response syndrome and retinopathy of prematurity.NICHD neonatal research network. Pediatr. Res. 2010 Apr;67(4): 394-400.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Chen S.N., Lian I., Hwang Y.C., Chen Y.H., Chang Y.C., Lee K.H., Chuang C.C., Wu W.C. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Retina. 2015; 35: 667-74.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Tufail А. et al. late onset vitreoretinal complications of regressed ROP. Br. J. Ophthalmol. 2004; 88: 243-6.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Azizia M., Lloyd J., Allen M., Klein N., Peebles D. Immune status in very preterm neonates. Pediatrics.2012 Apr;129(4): 967-74.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Dembinski J., Behrendt D., Martini R., Heep A., Bartmann P. Modulation of pro- and anti-inflammatory cytokine production in very preterm infants. Cytokine. 2003; 21: 200-6.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Schultz C., Rott C., Temming P., Schlenke P., Moller J.C., Bucsky P. Enhanced interleukin-6 and interleukin-8 synthesis in term and preterm infants. Pediatr. Res. 2002; 51: 317-22.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Strunk T., Currie A., Richmond P., Simmer K., Burgner D. Innate immunity in human newborn infants: prematurity means more than immaturity. J. Matern. Fetal Neonatal Med. 2011 Jan; 24(1): 25-31.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Алакаева И.Б. Особенности гемопоэза во внутриутробном периоде и влияние на него внутриутробных инфекций. Педиатрия. 2009; (4): 122-5.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Володин Н.Н. Иммунология интранатального периода: проблемы и перспективы. Педиатрия. 2001; 4: 4-8.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Чистякова Г.Н., Чарипова Б.Т., Тарасова М.Н., Билимова С.И., Газиева И.А. Ремизова И.И. Особенности состояния иммунной системы и характер микробной колонизации детей с экстремально низкой массой тела при рождении. Педиатрия.Журнал им.Г.Н.Сперанского.2013; 92( 2): 42-8.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Belderbos M.E., van Bleek G.M., Levy O., Blanken M.O., Houben M.L., Schuijff L, Kimpen J.L., Bont L. Skewed pattern of Toll-like receptor 4-mediated cytokine production in human neonatal blood: Low LPS-induced IL-12p70 and high IL-10 persist throughout the first month of life. Clin. Immunol. 2009; 133: 228-37.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Hartel C., Osthues I., Rupp J., Haase B., Roder K., Gopel W., Herting E., Schultz C. Characterisation of the host inflammatory response to Staphylococcus epidermidis in neonatal whole blood. Arch Dis Child Fetal Neonatal Ed. 2008; 93: 140-5.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Schultz C., Temming P., Bucsky P., Gopel W., Strunk T., Hartel C. Immature anti-inflammatory response in neonates. Clin. Exp. Immunol. 2004;135: 130-6.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Tatad A.M., Nesin M., Peoples J., Cheung S., Lin H., Sison C., Perlman J., Cunningham-Rundles S. Cytokine expression in response to bacterial antigens in preterm and term infant cord blood monocytes. Neonatology. 2008; 94: 8-15.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Катаргина Л.А., Слепова О.С., Белова М.В., Андрюшин А.Е.Значение нарушений цитокинового статуса в патогенезе поздних витреоретинальных осложнений ретинопатии недоношенных. Рос. педиатр. офтальмол. 2013; (2): 14-7.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Катаргина Л.А. , Коголева Л.В., Белова М.В., Денисова Е.В. Поздние отслойки сетчатки при ретинопатии недоношенных. Офтальмохирургия. 2009; (3): 31-4.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Mutlu F.M., Sarici S.U. Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. Int. J. Ophthalmol. 2013; 6: 228-36.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Kojima H., Otani A., Oishi A., Makiyama Y., Nakagawa S., Yoshimura N. Granulocyte colony-stimulating factor attenuates oxidative stress-induced apoptosis in vascular endothelial cells and exhibits functional and morphologic protective effect in oxygen-induced retinopathy. Blood. 2011; 117: 1091-100.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Sato T., Kusaka S., Shimojo H., Fujikado T. Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology. 2009; 116: 2165-9.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Connor K.M., SanGiovanni J.P., Lofqvist C., Aderman C.M., Chen J., Higuchi A., Hong S., Pravda E.A., Majchrzak S., Carper D., et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat.Med. 2007; 13: 868-73.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Hunt S. Increased dietary intake of omega-3-PUFA reduces pathological retinal angiogenesis. Ophthalmology. 2007; 104: 727-9.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Stahl A., Sapieha P., Connor K.M., Sangiovanni J.P., Chen J., Aderman C.M., Willett K.L., Krah N.M., Dennison R.J., Seaward M.R., et al. Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathy. Circ. Res. 2010; 107: 495-500.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Flor-de-Lima F., Rocha G., Proença E., Tafulo S., Freitas F., Guimarães H. The role of the human leukocyte antigen system in retinopathy of prematurity: a pilot study. 2013 Dec;102(12): 1150-3.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Балашова Л.М., Быковская С.Н., Кузнецова Ю.Д., Коробова Л.С. Количественные и функциональные нарушения показателей клеточного иммунитета у взрослых, пожилых людей, соматически здоровых детей и больных ретинопатией недоношенных. Клин. геронтол. 2012; 18(11-12): 76-7.</mixed-citation></ref></ref-list></back></article>
